
Devyser Diagnostics Q2 - Entering a potentially case altering phase

Redeye sees Q2 sales in line with our forecast but higher costs, prompting us to lower our 2024e EBIT assumptions. Our longer-term estimates are untouched. The share trades in pair with its peers and near our base case, but we point to our estimates taking a conservative approach to the Thermo Fischer deal /US sales – this might be reconsidered as more of this potentially case altering collaboration should materialise during H2 2024.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Devyser Diagnostics Q2 - Entering a potentially case altering phase](#)